CN Patent

CN112437766A — 制备贝派地酸及其组合物的方法

Assigned to Esperion Therapeutics Inc · Expires 2021-03-02 · 5y expired

What this patent protects

本发明提供了制备8‑羟基‑2,2,14,14‑四甲基十五烷二酸的方法和制备包含纯化量的8‑羟基‑2,2,14,14‑四甲基十五烷二酸的药物材料的方法。还提供了包含纯化量的8‑羟基‑2,2,14,14‑四甲基十五烷二酸的组合物和药物材料以及使用该组合物和药物材料治疗各种疾病和病况的方法。

USPTO Abstract

本发明提供了制备8‑羟基‑2,2,14,14‑四甲基十五烷二酸的方法和制备包含纯化量的8‑羟基‑2,2,14,14‑四甲基十五烷二酸的药物材料的方法。还提供了包含纯化量的8‑羟基‑2,2,14,14‑四甲基十五烷二酸的组合物和药物材料以及使用该组合物和药物材料治疗各种疾病和病况的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112437766A
Jurisdiction
CN
Classification
—
Expires
2021-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Esperion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.